Google Übersetzer
About
Alphamab Oncology (HK:9966) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
Apr 22 2026
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
Apr 1 2026
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
Mar 26 2026
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
Mar 24 2026
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
Financials
Revenue
HK$566.24 M
Market Cap
HK$8.76 B
EPS
0.23